1. Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune cell profile.
- Author
-
Churchill M, Chadburn A, Bilinski RT, and Bertagnolli MM
- Subjects
- Adenomatous Polyposis Coli Protein, Animals, B-Lymphocytes drug effects, B-Lymphocytes pathology, CD4 Lymphocyte Count drug effects, CD4-Positive T-Lymphocytes pathology, Cytoskeletal Proteins genetics, Germ-Line Mutation, Immunohistochemistry, Intestinal Mucosa drug effects, Intestinal Neoplasms genetics, Lymphocyte Count drug effects, Mice, Mice, Inbred C57BL, Mice, Mutant Strains genetics, Antineoplastic Agents pharmacology, Curcumin pharmacology, Immune System cytology, Immune System drug effects, Intestinal Mucosa pathology, Intestinal Neoplasms prevention & control, Intestines cytology, Intestines drug effects
- Abstract
Background: The C57BL/6J-Min/+ (Min/+) mouse bears a germline mutation in Apc and is therefore a model for familial adenomatous polyposis and sporadic colorectal cancer. Min/+ intestinal mucosa exhibits a marked tendency for spontaneous adenoma formation. Curcumin is a phenolic antioxidant known for its antitumor and immune modulatory functions in vitro. Curcumin prevents adenoma formation in Min/+ mice, through a mechanism that may be related to its immunomodulatory properties., Materials and Methods: To study the relationship between intestinal immunity and curcumin-induced antitumor response, we used immunohistochemistry to characterize the effect of curcumin treatment on resident intestinal immune effector cells in Min/+ mice., Results/conclusion: These results show that mucosal CD4(+) T cells and B cells increase in animals treated with curcumin, suggesting that curcumin modulates lymphocyte-mediated immune functions., (Copyright 2000 Academic Press.)
- Published
- 2000
- Full Text
- View/download PDF